Is There Anything New in Canine AGASACA?

Area of Science:

• Veterinary Oncology
• Comparative Pathology

Background:

• Apocrine gland anal sac adenocarcinoma (AGASACA) is a locally invasive canine tumor.
• High rates of metastasis to lymph nodes (23.4-83%) and distant organs (2.1-31%) are observed at diagnosis.
• Paraneoplastic hypercalcemia affects 16-53% of affected dogs.

Purpose of the Study:

• To provide a comprehensive overview of AGASACA.
• To highlight recent advancements in diagnosis, staging, treatment, and prognosis.
• To focus on updated prognostic variables and therapeutic strategies.

Main Methods:

• Critical review of current scientific literature on AGASACA.
• Analysis of data regarding treatment outcomes and prognostic factors.
• Synthesis of information on histological diagnosis, staging, and therapeutic options.

Main Results:

• Surgery with adjuvant therapy improves median survival time (MST) to 15-28 months compared to chemotherapy alone (6.9-8.7 months).
• Radiation therapy as sole or adjunctive treatment yields the highest MST (22-32 months).
• Negative prognostic factors include primary tumor size, lymph node metastasis, distant metastasis, and tumor histology.

Conclusions:

• AGASACA requires prompt diagnosis and multimodal treatment.
• Radiation therapy shows significant promise for improving survival outcomes.
• Understanding prognostic variables is crucial for effective management of canine AGASACA.